3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
23
Burkitt Lymphoma
14
Sarcoma
13
Neoplasms
11
Lymphoma, Follicular
11
Lymphoma
10
Hodgkin Disease
9
Breast Neoplasms
9
Triple Negative Breast Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Non-Hodgkin
8
Endometrial Neoplasms
8
Ovarian Neoplasms
7
Lymphoma, B-Cell
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Wilms Tumor
4
Recurrence
4
Osteosarcoma
4
Neoplasm Metastasis
4
Liposarcoma
4
Fallopian Tube Neoplasms
4
Sarcoma, Ewing
3
Neuroblastoma
3
Lymphoproliferative Disorders
3
Lymphoma, T-Cell
3
Lymphoma, Mantle-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Biphenotypic, Acute
3
Leiomyosarcoma
3
Interventions
Cyclophosphamide
3
acalabrutinib
2
Rituximab
2
pembrolizumab
1
obinutuzumab
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Vincristine
1
Tacrolimus
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Doxorubicin
1
CA-4948
1
Busulfan
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Diseases
×
Doxorubicin
×
90 days
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled